RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
Clinical trials for RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER explained in plain language.
Never miss a new study
Get alerted when new RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER trials appear
Sign up with your email to follow new studies for RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough thyroid cancers: drug combo trial launches
Disease control Recruiting nowThis study tests two drugs, sacituzumab tirumotecan and tislelizumab, in people with advanced thyroid cancer that has stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or help people live longer. About 94 adults with three types of har…
Matched conditions: RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
Phase: NA • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New radioactive drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, [177Lu]Lu-AKIR001, in 15 adults with advanced solid tumors (like thyroid, head and neck, cervical, vulvar, or lung cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and sid…
Matched conditions: RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
Phase: EARLY_PHASE1 • Sponsor: Karolinska University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC